EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real-World Outcomes of First-Line Treatment With Anti–PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States

Stephen V Liu iD, Anandaroop Dasgupta, Dominick Latremouille-Viau iD, Carmine Rossi iD, Pragya Rai iD, Fabrice Barlesi, Ticiana A Leal iD

JCO Global Oncology · 2024

DOI: 10.1200/go.24.00138 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Stephen V Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Anti–PD-1/PD(L)1-based combination therapy is the standard of care in first line (1L) for metastatic nonsquamous non–small cell lung cancer (mnsqNSCLC) without driver alterations. This study aimed to evaluate real-world clinical outcomes in this population. METHODS Eligible physicians in the United States, Europe, and Japan abstracted information from medical charts of eligible adult patients with mnsqNSCLC (without EGFR/ ALK, no known ROS1 alterations) who initiated 1L anti–PD(L)1-based combination therapy for mnsqNSCLC between 2017 and 2021. Kaplan-Meier analyses were used to assess overall survival (OS), time-to-treatment discontinuation (TTD), and real-world progression-free survival (rwPFS) after 1L initiation. RESULTS Overall, 142 physicians contributed deidentified data from 430 patients' medical charts. The distribution of PD-L1 expression levels was 31.2% with tumor proportion score (TPS)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsB7-H1 AntigenHumansMaleFemaleUnited StatesAgedEuropeJapanMiddle AgedImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsAged, 80 and overAdultRetrospective StudiesTreatment Outcome

Substanzen

B7-H1 AntigenImmune Checkpoint InhibitorsCD274 protein, human

Autor:innen und Institutionen

  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
  • Eisai Inc, Nutley, NJ.
  • Analysis Group, Inc, Montréal, Canada.
  • Merck & Co, Inc, Rahway, NJ.
  • Gustave Roussy Institute, Paris Saclay University, Paris, France.
  • Winship Cancer Institute, Emory University, Atlanta, GA.

ORCID-Profile: Stephen V Liu, Dominick Latremouille-Viau, Carmine Rossi, Pragya Rai, Ticiana A Leal

Zitieren

APA

Liu, S. V., Dasgupta, A., Latremouille-Viau, D., Rossi, C., Rai, P., Barlesi, F., & Leal, T. A. (2024). Real-World Outcomes of First-Line Treatment With Anti–PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States. JCO Global Oncology. https://doi.org/10.1200/go.24.00138

Vancouver

Liu SV, Dasgupta A, Latremouille-Viau D, Rossi C, Rai P, Barlesi F, et al. Real-World Outcomes of First-Line Treatment With Anti–PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States. JCO Global Oncology. 2024. doi:10.1200/go.24.00138

BibTeX
@article{Liu2024,
  author = {Liu, Stephen V and Dasgupta, Anandaroop and Latremouille-Viau, Dominick and Rossi, Carmine and Rai, Pragya and Barlesi, Fabrice and Leal, Ticiana A},
  title = {Real-World Outcomes of First-Line Treatment With Anti–PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States},
  journal = {JCO Global Oncology},
  year = {2024},
  doi = {10.1200/go.24.00138}
}
Kostenlos starten →